Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats.
Antibody charge variants have gained considerable attention in the biotechnology industry due to their potential influence on stability and biological activity. Subtle differences in the relative proportions of charge variants are often observed during routine biomanufacture or process changes and pose a challenge to demonstrating product comparability. To gain further insights into the impact on biological activity and pharmacokinetics (PK) of monoclonal antibody (mAb) charge heterogeneity, we isolated the major charge forms of a recombinant humanized IgG1 and compared their in vitro properties and in vivo PK. The mAb starting material had a pI range of 8.7-9.1 and was composed of about 20% acidic variants, 12% basic variants, and 68% main peak. Cation exchange displacement chromatography was used to isolate the acidic, basic, and main peak fractions for animal studies. Detailed analyses were performed on the isolated fractions to identify specific chemical modification contributing to the charge differences, and were also characterized for purity and in vitro potency prior to being administered either subcutaneously (SC) or intravenously (IV) in rats. All isolated materials had similar potency and rat FcRn binding relative to the starting material. Following IV or SC administration (10 mg/kg) in rats, no difference in serum PK was observed, indicating that physiochemical modifications and pI differences among charge variants were not sufficient to result in PK changes. Thus, these results provided meaningful information for the comparative evaluation of charge-related heterogeneity of mAbs, and suggested that charge variants of IgGs do not affect the in vitro potency, FcRn binding affinity, or the PK properties in rats.
Khawli
Leslie A
LA
Department of Pharmacokinetic and Pharmacodynamic Sciences, Genentech, Inc., South San Francisco, CA, USA. khawli.leslie@gene.com
Goswami
Sirj
S
Hutchinson
Ryan
R
Kwong
Zephania W
ZW
Yang
Jihong
J
Wang
Xiangdan
X
Yao
Zhenling
Z
Sreedhara
Alavattam
A
Cano
Tony
T
Tesar
Devin
D
Nijem
Ihsan
I
Allison
David E
DE
Wong
Pin Yee
PY
Kao
Yung-Hsiang
YH
Quan
Cynthia
C
Joshi
Amita
A
Harris
Reed J
RJ
Motchnik
Paul
P
D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry* / Q000493:pharmacokinetics*; D002852:Chromatography, Ion Exchange; D007074:Immunoglobulin G / Q000737:chemistry*; D007700:Kinetics; D051381:Rats
D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G
Nat Rev Immunol. 2007 Sep;7(9):715-25
17703228
Pharm Res. 2000 Sep;17(9):1110-7
11087044
J Immunol. 2009 Jun 15;182(12):7663-71
19494290
Traffic. 2000 Jun;1(6):480-93
11208134
Biochemistry. 1986 Dec 30;25(26):8343-7
3030393
FASEB J. 1987 Sep;1(3):229-35
3623000
Anal Chem. 2005 Mar 1;77(5):1432-9
15732928
Nat Rev Cancer. 2001 Nov;1(2):118-29
11905803
Methods Find Exp Clin Pharmacol. 2004 Mar;26(2):123-7
15071611
Nat Biotechnol. 2004 Nov;22(11):1383-91
15529163
J Pharm Sci. 2007 Jan;96(1):1-26
16998873
J Immunol. 1998 Apr 1;160(7):3393-402
9531299
Anal Biochem. 2007 Jan 1;360(1):75-83
17113563
J Biol Chem. 2008 Jun 6;283(23):16194-205
18339624
J Chromatogr B Analyt Technol Biomed Life Sci. 2007 May 1;850(1-2):285-94
17182291
Hybridoma. 1987 Jun;6(3):229-40
3110049
Pharm Res. 1999 Mar;16(3):350-8
10213364
J Chromatogr B Biomed Sci Appl. 2001 Mar 10;752(2):233-45
11270864
Q J Nucl Med. 1997 Mar;41(1):25-35
9195850
Protein Eng Des Sel. 2010 May;23(5):385-92
20159773
Anal Biochem. 2006 Jan 1;348(1):24-39
16289440
Cancer Res. 1984 Sep;44(9):3719-23
6744289
Neoplasia. 2007 Dec;9(12):1099-110
18084617
Nat Biotechnol. 2007 May;25(5):537-8
17483836
Trends Biotechnol. 2010 Oct;28(10):509-16
20691488
Electrophoresis. 2009 Mar;30(5):714-22
19199293
J Immunol. 1999 Dec 1;163(11):6072-7
10570296
Physiol Rev. 1990 Oct;70(4):987-1028
2217560
J Pharm Sci. 1999 Jan;88(1):147-53
9874717
Biochim Biophys Acta. 2002 Mar 25;1595(1-2):235-49
11983399
J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jun 1;852(1-2):250-6
17296336
Nucl Med Biol. 1996 Apr;23(3):257-61
8782234
Cancer Biother Radiopharm. 1996 Jun;11(3):203-15
10851539
J Biol Chem. 2001 Mar 2;276(9):6591-604
11096108
Proc R Soc Lond B Biol Sci. 1966 Nov 22;166(1003):114-23
4382921
Drug Discov Today Technol. 2005 Spring;2(1):89-96
24981760
Glycobiology. 2007 May;17(5):529-40
17331977
Nat Biotechnol. 2005 Sep;23(9):1054-8
16151390
Biophys J. 1997 Jan;72(1):65-76
8994593
Biotechnol Prog. 2002 May-Jun;18(3):509-13
12052067
Int Immunol. 2001 Dec;13(12):1551-9
11717196
J Pharm Sci. 2004 Sep;93(9):2184-204
15295780
Bioconjug Chem. 2003 May-Jun;14(3):546-53
12757378
Proc Natl Acad Sci U S A. 1986 Apr;83(8):2632-6
3458222
Int Immunol. 2006 Dec;18(12):1759-69
17077181
J Biol Chem. 1977 Mar 25;252(6):1865-8
845149
Q J Nucl Med. 1998 Dec;42(4):242-9
9973839
Biochemistry. 1999 Sep 28;38(39):12639-47
10504233
Protein Sci. 2009 Feb;18(2):424-33
19165723
Cancer Biother Radiopharm. 2002 Aug;17(4):359-70
12396700
Int J Pharm. 2006 Feb 3;308(1-2):46-51
16316730
Curr Pharm Biotechnol. 2008 Dec;9(6):468-81
19075686
Eur J Nucl Med. 1990;17(6-8):305-9
2286203
Biochem Soc Trans. 2002 Aug;30(4):481-6
12196119
Electrophoresis. 2006 Sep;27(18):3584-90
16927345
J Biol Chem. 2008 Jun 6;283(23):16206-15
18339626
J Pharmacol Exp Ther. 1996 Jan;276(1):246-52
8558438
Nucl Med Biol. 2007 Oct;34(7):757-78
17921028
J Med Chem. 2004 Mar 11;47(6):1465-74
14998334
Cancer Res. 2010 Feb 15;70(4):1277-80
20124473